Young researchers receive boost to develop innovative treatment for melanoma

Young researchers receive boost to develop innovative treatment for melanoma

4 March 2021

Melanoma research has received a boost with two researchers from Melanoma Institute Australia (MIA) and The University of Sydney awarded highly competitive fellowships from Cancer Institute NSW.

Dr Tuba Nur Gide and Dr Camelia Quek were each awarded an Early Career Fellowship to support their innovative research into melanoma treatment. The Fellowships are designed to encourage promising early career researchers who recently completed their PhD to choose cancer as their selected field of research endeavor.

“It is deeply rewarding to see these two talented young researchers receive these prestigious Fellowships,” said Prof Richard Scolyer, Co-Medical Director of MIA. “Their dedication and passion for developing more effective treatments for patients is inspiring and we are proud to have them as part of our team.”

While immunotherapy is proving effective in treating many advanced melanoma patients, others either don’t respond or develop resistance. These treatments can also cause significant, life-altering side-effects. Dr Nur Guide and Dr Quek are trying to identify which patients will respond to treatment and why, as this is essential to improving survival and quality of life for advanced melanoma patients around the world.

Prof Georgina Long AO, Co-Medical Director of MIA, is delighted that Dr Nur Guide and Dr Quek have received funding to pursue their research endeavors.

“Supporting medical research into Australia’s national cancer is vital to improving care for melanoma patients,” commented Prof Long. “With Australia at the forefront of global melanoma research efforts, it is exciting that our early career researchers will have the support they need to pioneer new treatments to improve the lives of melanoma patients.”

Personalised immunotherapy

There are currently no effective tests to determine which patients will respond to immunotherapy and which will need another treatment to stop their melanoma progressing. Dr Nur Gide’s research project is investigating this by assessing the accuracy of a panel of predictive tests with the aim of taking this out of the lab and into the everyday clinic setting.

“Once a patient enters a clinic, in real time we will be able to determine if they are likely to respond to treatment,” said Dr Nur Gide. “This will allow patients to avoid unnecessary toxicities and limit costs to patients and the healthcare system, as well as ultimately improving survival outcomes.”

The research project will help change the way cancer patients are treated and selected for clinical trials, by moving away from the one-size-fits-all approach and towards a precision approach to delivering effective immunotherapies on a personal basis.

“It is a great honour to have been awarded the CINSW Early Career Fellowship,” said Dr Nur Gide. “It will allow me to continue conducting research that will positively impact the lives of patients with advanced cancer and contribute to achieving our goal of zero deaths from melanoma.”

Understanding resistance to immunotherapy

Dr Camelia Quek’s research is trying to understand why some people with advanced melanoma become resistant to immunotherapy after they receive treatment. She is investigating the relatively new concept that a tumour and the microenvironment around it can evolve, causing resistance to immunotherapy. She will be using innovative computational biology methods to identify which genes and proteins involved in immune control are altered.

“Ultimately my research will provide significant benefits in developing innovative drug combination strategies and novel therapeutic targets to improve treatment for melanoma patients,” commented Dr Quek. “This will improve survival for patients, as well as improve their quality of life.”

“This fellowship will provide a fantastic opportunity for me to continue making discoveries that enable the development of innovative treatment strategies and biomarkers, ensuring the prolonged survival of Australians with cancer,” she said.

 

Challenges in melanoma clinical research: A snapshot from the Australasian Melanoma Conference 2016
05 Dec 2016

Challenges in melanoma clinical research

The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.

Global Melanoma Research Report
01 Dec 2016

Global Melanoma Research Report

Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.

Announcement from Melanoma Institute Australia
24 Nov 2016

Announcement from Melanoma Institute Australia

After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.

Nine practice points from the new melanoma guidelines
17 Nov 2016

Nine practice points from the new melanoma guidelines

Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.  

Melanoma under 40
17 Nov 2016

Melanoma under 40

Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.

Don't let sunburn be your summer holiday souvenir
11 Nov 2016

Don't let sunburn be your summer holiday souvenir

Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.

Using clinical features to identify patients at high risk for melanoma
10 Nov 2016

Using clinical features to identify patients at high risk for melanoma

Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?

MIA congratulates Professor Georgina Long
09 Nov 2016

Congratulations to Professor Georgina Long

Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).

Tags: more news
Uniting our global researchers for melanoma
28 Oct 2016

Uniting our global researchers for melanoma

The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.

Best practice guidelines for melanoma care go digital
28 Oct 2016

Best practice guidelines for melanoma care go digital

Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.

Awards and honours for our talented researchers
26 Oct 2016

Awards and honours for our talented researchers

Congratulations are in order for two of our talented researchers.

5 Minutes With Prof Richard Scolyer
21 Oct 2016

5 Minutes With Prof Richard Scolyer

Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on. 

Research spotlight: High Risk Clinic
10 Oct 2016

Research spotlight: High Risk Clinic

Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.

Learning from the best in the world
05 Oct 2016

Learning from the best in the world

A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.

Uniting the world for a cure
30 Sep 2016

Uniting the world for a cure

MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients

A Day in the Life of... Michelle Peranec
30 Sep 2016

A Day in the Life of... Michelle Peranec

Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.

Wildfire Award helps ignite new melanoma research
08 Sep 2016

Wildfire Award helps ignite new melanoma research

Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.

Opinion: Fighting the Resistance
25 Aug 2016

Opinion: Fighting the Resistance

Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.

5 Minutes With A/Prof Jennifer Wargo
11 Aug 2016

5 Minutes With A/Prof Jennifer Wargo

A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.

Dr James Wilmott awarded for outstanding cancer research
06 Aug 2016

Dr James Wilmott awarded for outstanding cancer research

Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.